T-cell receptor specific for MHC class II-tetanus toxin P30 peptide complex (TCR-P30)

The T-cell receptor (TCR) specific for MHC II–P30 complexes is an immune receptor that recognizes a universal epitope from the tetanus toxin (P30 peptide, residues 947–967) presented by Major Histocompatibility Complex class II (MHC II) molecules, primarily HLA-DR (Panina-Bordignon et al., 1989, Eur. J. Immunol.). The P30 peptide is highly promiscuous, meaning it can be presented by a wide variety of HLA-DR alleles common in the human population, making this TCR a potent mediator of CD4+ T-cell help (Demotz et al., 1989, J. Immunol.). In therapeutic contexts, this TCR is utilized in TCR-engineered T-cell (TCR-T) therapies to provide essential helper signals, such as the secretion of IL-2 and IFN-gamma, which enhance the efficacy and persistence of CD8+ cytotoxic T cells against tumors (Knochelmann et al., 2018, Front. Immunol.). By targeting the P30-MHC II complex, researchers can bypass the need for patient-specific neoantigens in certain universal immunotherapy designs. The receptor is also a critical tool in studying MHC II-restricted antigen presentation and the orchestration of adaptive immune responses in both infectious disease and oncology. Its interaction with the P30 peptide serves as a model for robust, non-self antigen recognition that can be co-opted to overcome the immunosuppressive tumor microenvironment.

Other names

Tetanus toxin P30-specific T-cell receptorHLA-DR-restricted P30 TCRTT947-967-specific TCRP30-specific TCR

The TCR binds specifically to the P30 peptide (FNNFTVSFWLRVPKVSASHLE) derived from tetanus toxin when it is presented on MHC class II (HLA-DR) molecules; this binding event triggers the CD3 signaling cascade, leading to CD4+ T-cell activation, proliferation, and the secretion of pro-inflammatory cytokines.